GDF11 enhances therapeutic efficacy of mesenchymal stem cells for myocardial infarction via YME1L-mediated OPA1 processing

Yun Zhao, Jinyun Zhu, Ning Zhang, Qi Liu, Yingchao Wang, Xinyang Hu, Jinghai Chen, Wei Zhu, Hong YuStem 2020 · DOI

TL;DR

This study reveals that Growth Differentiation Factor 11 (GDF11) significantly boosts the survival and therapeutic effectiveness of mesenchymal stem cells (MSCs) under the harsh conditions of a heart attack. By preserving mitochondrial health through a specific signaling pathway, GDF11-enhanced MSCs lead to improved cardiac function and reduced scar tissue in animal models.

What Problem Does This Paper Address?

Myocardial infarction (MI), or heart attack, causes significant damage to the heart muscle, leading to irreversible loss of cardiomyocytes and scar formation. Stem cell therapy, particularly using mesenchymal stem cells (MSCs), holds promise for treating MI by promoting repair and regeneration. However, a major hurdle is the poor survival rate of transplanted MSCs in the hostile, oxygen-deprived (hypoxic) environment of an infarcted heart. This limits their therapeutic efficacy. The authors investigate whether GDF11, a growth factor known to promote stem cell activity, can overcome this limitation by enhancing MSC viability and function in the context of cardiac injury.

Methods

The researchers employed a multi-pronged approach:

  • In vitro studies:
    • Cell Culture: Mouse cardiac MSCs were cultured under both normal (normoxic) and low-oxygen (hypoxic) conditions.
  • GDF11 Treatment: MSCs were treated with recombinant GDF11 (MSCs<sup>rGDF11</sup>) or genetically engineered to overexpress GDF11 (MSCs<sup>LV-GDF11</sup>) using lentiviral vectors.
  • Apoptosis Assays: TUNEL staining and Western blotting for cleaved caspases (caspase-3 and -9) were used to measure cell death.
  • Paracrine Function Assays: Conditioned media from treated MSCs were used to assess their ability to promote blood vessel formation (tube formation assay with HUVECs) and protect cardiomyocytes from apoptosis. VEGF levels were measured via ELISA.
  • Mitochondrial Analysis: Transmission electron microscopy (TEM) was used to examine mitochondrial morphology. Oxygen consumption rate (OCR) was measured using a Seahorse XF analyzer. ATP production and mitochondrial membrane potential were assessed using specific kits and TMRM staining, respectively.
  • Signaling Pathway Investigation: Western blotting was used to analyze the expression and phosphorylation of key proteins in the TGF-β/Smad pathway (p-Smad2/3, ALK5). Inhibitors of TGF-β receptor (SB431542) and Smad3 (SIS3) were used to block specific pathways. siRNA was used to knock down genes of interest (GDF11, OPA1, YME1L).
  • In vivo studies:
    • Myocardial Infarction Model: A standard mouse model of MI was created by ligating the left anterior descending coronary artery.
  • Cell Transplantation: GDF11-overexpressing MSCs (MSCs<sup>LV-GDF11</sup>) or control MSCs (MSCs<sup>LV</sup>) were injected into the peri-infarct zone of the hearts.
  • Cardiac Function Assessment: Echocardiography was used to measure left ventricular ejection fraction (LVEF) and fractional shortening (LVFS) over time.
  • Histological Analysis: Immunofluorescence staining was used to assess MSC retention (GFP), angiogenesis (CD31 for capillaries, α-SMA for smooth muscle cells), and scar size.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • GDF11 as a Guardian of MSCs: The most striking finding is that GDF11 acts as a potent protector for MSCs under hypoxic stress, significantly reducing apoptosis and preserving their function. This directly addresses the critical issue of poor stem cell survival in injured hearts.
  • Mitochondrial Health is Key: GDF11's protective effect is strongly linked to maintaining the health and integrity of mitochondria. It prevents mitochondrial fragmentation and preserves their ability to generate energy (ATP) and maintain membrane potential, even under oxygen deprivation.
  • The YME1L-OPA1 Axis: The study uncovers a specific molecular mechanism: GDF11 upregulates the mitochondrial protease YME1L, which in turn influences the processing of OPA1. This rebalancing of OPA1 isoforms is crucial for promoting mitochondrial fusion and preventing fission, thereby maintaining mitochondrial structure and function.
  • TGF-β/Smad Pathway as the Conductor: GDF11 exerts its effects by activating the TGF-β receptor (specifically ALK5) and downstream Smad2/3 signaling. This pathway ultimately leads to the upregulation of YME1L, highlighting a well-established signaling cascade being repurposed for stem cell protection.
  • Therapeutic Potential Realized: In vivo experiments confirmed that GDF11-enhanced MSCs not only survive better but also lead to improved cardiac function, increased blood vessel formation, and reduced scar size in a mouse model of heart attack.

Key Results

  • In vitro:
    • GDF11 treatment (rGDF11 or LV-GDF11) significantly reduced MSC apoptosis under hypoxia.
  • GDF11 enhanced the paracrine function of MSCs, increasing VEGFA secretion and promoting HUVEC tube formation.
  • GDF11 preserved mitochondrial morphology and function (higher OCR, ATP production, and membrane potential) under hypoxia.
  • GDF11 upregulated YME1L expression and promoted L-OPA1 processing, which was dependent on the ALK5-Smad2/3 pathway.
  • Knockdown of OPA1 or YME1L abolished the protective effects of GDF11.
  • In vivo:
    • Transplantation of MSCs<sup>LV-GDF11</sup> resulted in better cardiac function (higher LVEF and LVFS) compared to control MSCs.
  • Increased MSC retention and reduced apoptosis were observed in the peri-infarct area of hearts treated with MSCs<sup>LV-GDF11</sup>.
  • Improved angiogenesis and smaller scar size were noted in the GDF11-treated group.

Limitations and Future Work

  • Tissue Specificity: The authors acknowledge that GDF11's role can be tissue-specific, and while they focused on cardiac MSCs, further investigation might be needed for MSCs from other sources.
  • Non-canonical Pathways: While the study highlights the ALK5-Smad2/3 pathway, the authors suggest that other non-canonical signaling pathways (like AKT, AMPK, ERK1/2) might also be involved in GDF11's modulation of mitochondrial functions and warrant further investigation.
  • Clinical Translation: While promising, the findings are from preclinical animal models. Future work would involve translating these findings into clinical applications for treating human myocardial infarction.
  • Long-term Effects: The study demonstrates short-term benefits. Long-term efficacy and safety of GDF11-enhanced MSC therapy would need to be thoroughly evaluated.

Summary updated

Abstract

Growth differentiation factor 11 (GDF11) has been shown to promote stem cell activity, but little is known about the effect of GDF11 on viability and therapeutic efficacy of cardiac mesenchymal stem cells (MSCs) for cardiac injury. To understand the roles of GDF11 in MSCs, mouse heart-derived MSCs were transduced with lentiviral vector carrying genes for both GDF11 and green fluorescent protein (GFP) (MSCs<sup>LV-GDF11</sup> ) or cultured with recombinant GDF11 (MSCs<sup>rGDF11</sup> ). Either MSCs<sup>rGDF11</sup> or MSCs <sup>LV-GDF11</sup> displayed less cell apoptosis and better paracrine function, as well as preserved mitochondrial morphology and function under hypoxic condition as compared with control MSCs. GDF11 enhanced phosphorylation of Smad2/3, which upregulated expression of YME1L, a mitochondria protease that balances OPA1 processing. Inhibitors of TGF-β receptor (SB431542) or Smad2/3 (SIS3) attenuated the effects of GDF11 on cell viability, mitochondrial function, and expression of YME1L. Transplantation of MSCs<sup>GDF11</sup> into infarct heart resulted in improved cell survival and retention, leading to more angiogenesis, smaller scar size, and better cardiac function in comparison with control MSCs. GDF11 enhanced viability and therapeutic efficiency of MSCs by promoting mitochondrial fusion through TGF-β receptor/Smad2/3/YME1L-OPA1 signaling pathway. This novel role of GDF11 may be used for a new approach of stem cell therapy for myocardial infarction.
BibTeX
@inproceedings{zhao2020gdf,
  author = {Yun Zhao and Jinyun Zhu and Ning Zhang and Qi Liu and Yingchao Wang and Xinyang Hu and Jinghai Chen and Wei Zhu and Hong Yu},
  title = {{GDF11 enhances therapeutic efficacy of mesenchymal stem cells for myocardial infarction via YME1L-mediated OPA1 processing}},
  booktitle = {Stem},
  year = {2020},
  doi = {10.1002/sctm.20-0005},
}
Figure